Marc Casper Sells 275 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper sold 275 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Thermo Fisher Scientific Stock Up 1.0%

Shares of TMO stock traded up $6.33 on Wednesday, reaching $634.48. 1,842,596 shares of the company’s stock traded hands, compared to its average volume of 2,274,136. The company has a market capitalization of $234.60 billion, a P/E ratio of 34.13, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The business’s 50 day moving average price is $548.75 and its two-hundred day moving average price is $510.05.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the company posted $4.28 EPS. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently modified their holdings of the business. HighTower Advisors LLC increased its position in Thermo Fisher Scientific by 9.8% during the second quarter. HighTower Advisors LLC now owns 159,181 shares of the medical research company’s stock worth $79,807,000 after buying an additional 14,180 shares during the last quarter. Advus Financial Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $250,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $6,969,000. California State Teachers Retirement System raised its stake in shares of Thermo Fisher Scientific by 49,331.5% in the 2nd quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock valued at $141,711,778,000 after acquiring an additional 282,082,924 shares in the last quarter. Finally, Tanager Wealth Management LLP boosted its position in Thermo Fisher Scientific by 15.5% during the second quarter. Tanager Wealth Management LLP now owns 931 shares of the medical research company’s stock worth $467,000 after purchasing an additional 125 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TMO shares. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Barclays increased their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.